Serum and Urine Biomarkers Related to Kidney Fibrosis Predict Kidney Outcome in Czech Patients with IgA Nephropathy

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Feb 11

PMID 36768385

Authors

Michaela Neprasova

Dita Maixnerova

Nadja Sparding

Federica Genovese

Morten Asser Karsdal

Helena Koprivova

Marek Kollar

Miloslav Suchanek

Zdenka Hruskova

Vladimir Tesar

Affiliations

Soon will be listed here.

Abstract

We evaluated biomarkers related to kidney fibrosis for the outcome of patients with IgA nephropathy (IgAN). Clinical parameters (estimated glomerular filtration rate, hypertension, proteinuria) and histological findings were assessed in 134 patients with IgAN at the time of diagnosis and followed up prospectively (mean follow-up time, 56.5 months). We measured biomarkers of collagen and laminin turnover in serum and urine collected at the time of kidney biopsy using a novel enzyme-linked immunosorbent assay. Linear discriminant analysis and logistic regression models were used to predict the patient's kidney outcome. Five serum and urine biomarkers of laminin and collagen turnover (sLG1M, sPRO-C3, sPRO-C6, uPRO-C6/Cr, uC3M/Cr) could significantly differentiae IgAN patients with a worse prognosis. Clinical parameters (glomerular filtration rate (GFR), proteinuria) distinguished patients at risk of IgAN progression with a specificity of 87.3% and a sensitivity of 45.2% (area under the curve-AUC 0.751). The addition of the biomarkers significantly increased the prognostic ability with a specificity of 85.1% and a sensitivity of 73.3% (AUC 0.905). We have identified three serum (sLG1M, sPRO-C3, sPRO-C6) and two urinary markers (uPRO-C6/Cr, u-C3M /Cr) that significantly improve the prognostic ability of markers of kidney function to identify an IgAN patient's risk of progressing to ESKD.

Citing Articles

Urinary Endotrophin and Long-term Outcomes in Kidney Transplant Recipients.

Alkaff F, Kremer D, Thaunat O, Berger S, van den Born J, Genovese F Transplant Direct. 2025; 10(3):e1591.

PMID: 39877646 PMC: 11774563. DOI: 10.1097/TXD.0000000000001591.

Contemporary review of IgA nephropathy.

Filippone E, Gulati R, Farber J Front Immunol. 2024; 15:1436923.

PMID: 39188719 PMC: 11345586. DOI: 10.3389/fimmu.2024.1436923.

Blood and urine biomarkers of disease progression in IgA nephropathy.

Duan Z, Zhang C, Chen X, Cai G Biomark Res. 2024; 12(1):72.

PMID: 39075557 PMC: 11287988. DOI: 10.1186/s40364-024-00619-4.

Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets.

Reiss A, Jacob B, Zubair A, Srivastava A, Johnson M, Leon J J Clin Med. 2024; 13(7).

PMID: 38610646 PMC: 11012936. DOI: 10.3390/jcm13071881.

Unique Biomarkers of Collagen Type III Remodeling Reflect Different Information Regarding Pathological Kidney Tissue Alterations in Patients with IgA Nephropathy.

Sparding N, Neprasova M, Maixnerova D, Genovese F, Karsdal M, Kollar M Biomolecules. 2023; 13(7).

PMID: 37509129 PMC: 10377132. DOI: 10.3390/biom13071093.

References

Okonogi H, Nishimura M, Utsunomiya Y, Hamaguchi K, Tsuchida H, Miura Y . Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus. Clin Nephrol. 2001; 55(5):357-64. View

Nielsen M, Veidal S, Karsdal M, Orsnes-Leeming D, Vainer B, Gardner S . Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver Int. 2014; 35(2):429-37. DOI: 10.1111/liv.12700. View

Catania J, Chen G, Parrish A . Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol. 2006; 292(3):F905-11. DOI: 10.1152/ajprenal.00421.2006. View

Genovese F, Manresa A, Leeming D, Karsdal M, Boor P . The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?. Fibrogenesis Tissue Repair. 2014; 7(1):4. PMC: 3986639. DOI: 10.1186/1755-1536-7-4. View

Papasotiriou M, Genovese F, Klinkhammer B, Kunter U, Nielsen S, Karsdal M . Serum and urine markers of collagen degradation reflect renal fibrosis in experimental kidney diseases. Nephrol Dial Transplant. 2015; 30(7):1112-21. DOI: 10.1093/ndt/gfv063. View

Kawase T, Shimizu A, Adachi E, Tojimbara T, Nakajima I, Fuchinoue S . Collagen IV is upregulated in chronic transplant nephropathy. Transplant Proc. 2001; 33(1-2):1207-8. DOI: 10.1016/s0041-1345(00)02388-5. View

Abrahamson D, St John P . Laminin distribution in developing glomerular basement membranes. Kidney Int. 1993; 43(1):73-8. DOI: 10.1038/ki.1993.13. View

Gross M, Ritz E . Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease. Semin Dial. 2008; 21(4):308-18. DOI: 10.1111/j.1525-139X.2008.00454.x. View

Genovese F, Rasmussen D, Karsdal M, Jesky M, Ferro C, Fenton A . Imbalanced turnover of collagen type III is associated with disease progression and mortality in high-risk chronic kidney disease patients. Clin Kidney J. 2021; 14(2):593-601. PMC: 7886548. DOI: 10.1093/ckj/sfz174. View

10.

Zwirner J, Burg M, Schulze M, Brunkhorst R, Gotze O, Koch K . Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int. 1997; 51(4):1257-64. DOI: 10.1038/ki.1997.171. View

11.

Sun S, Henriksen K, Karsdal M, Byrjalsen I, Rittweger J, Armbrecht G . Collagen Type III and VI Turnover in Response to Long-Term Immobilization. PLoS One. 2015; 10(12):e0144525. PMC: 4671681. DOI: 10.1371/journal.pone.0144525. View

12.

Boor P, Ostendorf T, Floege J . Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol. 2010; 6(11):643-56. DOI: 10.1038/nrneph.2010.120. View

13.

Barbour S, Reich H . Risk stratification of patients with IgA nephropathy. Am J Kidney Dis. 2012; 59(6):865-73. DOI: 10.1053/j.ajkd.2012.02.326. View

14.

Janssen U, Bahlmann F, Kohl J, Zwirner J, Haubitz M, Floege J . Activation of the acute phase response and complement C3 in patients with IgA nephropathy. Am J Kidney Dis. 2000; 35(1):21-8. DOI: 10.1016/S0272-6386(00)70296-4. View

15.

Morita M, Uchigata Y, Hanai K, Ogawa Y, Iwamoto Y . Association of urinary type IV collagen with GFR decline in young patients with type 1 diabetes. Am J Kidney Dis. 2011; 58(6):915-20. DOI: 10.1053/j.ajkd.2011.04.019. View

16.

Holm Nielsen S, Rasmussen D, Brix S, Fenton A, Jesky M, Ferro C . A novel biomarker of laminin turnover is associated with disease progression and mortality in chronic kidney disease. PLoS One. 2018; 13(10):e0204239. PMC: 6166934. DOI: 10.1371/journal.pone.0204239. View

17.

Nielsen M, Nedergaard A, Sun S, Veidal S, Larsen L, Zheng Q . The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res. 2013; 5(3):303-15. PMC: 3633973. View

18.

Soylemezoglu O, Wild G, Dalley A, MacNeil S, Brown C, El Nahas A . Urinary and serum type III collagen: markers of renal fibrosis. Nephrol Dial Transplant. 1997; 12(9):1883-9. DOI: 10.1093/ndt/12.9.1883. View

19.

Stribos E, Holm Nielsen S, Brix S, Karsdal M, Seelen M, Goor H . Non-invasive quantification of collagen turnover in renal transplant recipients. PLoS One. 2017; 12(4):e0175898. PMC: 5400243. DOI: 10.1371/journal.pone.0175898. View

20.

Genovese F, Boor P, Papasotiriou M, Leeming D, Karsdal M, Floege J . Turnover of type III collagen reflects disease severity and is associated with progression and microinflammation in patients with IgA nephropathy. Nephrol Dial Transplant. 2015; 31(3):472-9. DOI: 10.1093/ndt/gfv301. View